390 related articles for article (PubMed ID: 18538839)
1. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.
Santana-Davila R; Tefferi A; Holtan SG; Ketterling RP; Dewald GW; Knudson RA; Steensma DP; Chen D; Hoyer JD; Hanson CA
Leuk Res; 2008 Dec; 32(12):1927-30. PubMed ID: 18538839
[TBL] [Abstract][Full Text] [Related]
2. Conventional cytogenetics in myelofibrosis: literature review and discussion.
Hussein K; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
[TBL] [Abstract][Full Text] [Related]
3. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.
Santana-Davila R; Holtan SG; Dewald GW; Ketterling RP; Knudson RA; Hanson CA; Steensma DP; Tefferi A
Leuk Res; 2008 Mar; 32(3):407-11. PubMed ID: 17707907
[TBL] [Abstract][Full Text] [Related]
5. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
[TBL] [Abstract][Full Text] [Related]
6. Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.
Muth M; Engelhardt BM; Kröger N; Hussein K; Schlué J; Büsche G; Kreipe HH; Bock O
Ann Hematol; 2011 Jan; 90(1):33-40. PubMed ID: 20625903
[TBL] [Abstract][Full Text] [Related]
7. Karyotype findings and molecular analysis of the bcr gene rearrangement supplementing the histologic classification of chronic myeloproliferative disorders.
Werner M; Nolte M; Kaloutsi V; Buhr T; Kausche F; Georgii A
Lab Invest; 1995 Apr; 72(4):405-10. PubMed ID: 7723278
[TBL] [Abstract][Full Text] [Related]
8. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
Dasanu CA; Schwartz RA; Bauer F; Davis LK; Silver JS; Reale MA
Leuk Res; 2011 May; 35(5):e41-3. PubMed ID: 21288571
[No Abstract] [Full Text] [Related]
10. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study.
Ahmed A; Powers MP; Youker KA; Rice L; Ewton A; Dunphy CH; Chang CC
Pathol Res Pract; 2009; 205(9):634-8. PubMed ID: 19446406
[TBL] [Abstract][Full Text] [Related]
11. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
Giagounidis AA; Germing U; Aul C
Clin Cancer Res; 2006 Jan; 12(1):5-10. PubMed ID: 16397017
[TBL] [Abstract][Full Text] [Related]
12. Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis.
Florena AM; Tripodo C; Di Bernardo A; Iannitto E; Guarnotta C; Porcasi R; Ingrao S; Abbadessa V; Franco V
J Clin Pathol; 2009 Apr; 62(4):331-8. PubMed ID: 19329711
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic conference. Chronic myeloproliferative disease with an increase in platelet count in the differential diagnosis of primary (essential, idiopathic) thrombocythemia (PTH)].
Zankovich R; Thiele J; Fischer R; Diehl V
Med Klin (Munich); 1986 Jan; 81(1):31-5. PubMed ID: 3785010
[No Abstract] [Full Text] [Related]
14. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.
Panteli K; Zagorianakou N; Bai M; Katsaraki A; Agnantis NJ; Bourantas K
Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419
[TBL] [Abstract][Full Text] [Related]
17. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
18. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Tefferi A; Levine RL; Kantarjian H
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
[TBL] [Abstract][Full Text] [Related]
20. Aberrant proplatelet formation in chronic myeloproliferative neoplasms.
Muth M; Büsche G; Bock O; Hussein K; Kreipe H
Leuk Res; 2010 Nov; 34(11):1424-9. PubMed ID: 20430444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
